Live Breaking News & Updates on Pollya Murphy

Stay updated with breaking news from Pollya murphy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Atea Pharmaceuticals (NASDAQ:AVIR) PT Lowered to $8.00

Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) had its price objective decreased by investment analysts at JPMorgan Chase & Co. from $10.00 to $8.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 26.98% from the […] ....

Pollya Murphy , Morgan Stanley , Zacks Investment Research , Atea Pharmaceuticals Company Profile Get Rating , Southstate Corp , Atea Pharmaceuticals , Jpmorgan Chase Co , Charles Schwab Investment Management Inc , Atea Pharmaceuticals Inc , Macquarie Group Ltd , Royal Bank , Get Rating , Investment Research , Director Polly , State Corp , Schwab Investment Management , Pharmaceuticals Company Profile , Nasdaq Avir , Lower Price Target , Jpmorgan Chase Co ,

Atea Pharmaceuticals (NASDAQ:AVIR) Posts Quarterly Earnings Results, Beats Expectations By $1.02 EPS

Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) posted its quarterly earnings results on Sunday. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $1.02, MarketWatch Earnings reports. Atea Pharmaceuticals had a return on equity of 20.59% and a net margin of 34.49%. NASDAQ AVIR opened at $6.46 on […] ....

Pollya Murphy , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , Thrivent Financial For Lutherans , De Shaw Co , Earnings History For Atea Pharmaceuticals , Atea Pharmaceuticals , Charles Schwab Investment Management Inc , Atea Pharmaceuticals Inc , Atea Pharmaceuticals Get Rating , Royal Bank , Get Rating , Marketwatch Earnings , Director Polly , Exchange Commission , Schwab Investment Management , Investment Research , Nasdaq Avir ,

Atea Pharmaceuticals (NASDAQ:AVIR) PT Lowered to $9.00 at SVB Leerink

Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) had its target price decreased by equities researchers at SVB Leerink from $10.00 to $9.00 in a report issued on Tuesday, Stock Target Advisor reports. The firm presently has a “market perform” rating on the stock. SVB Leerink’s price objective points to a potential upside of 41.96% from the […] ....

Pollya Murphy , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , Thrivent Financial For Lutherans , Southstate Corp , Lazard Asset Management , Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Atea Pharmaceuticals Get Rating , Macquarie Group Ltd , Royal Bank , Get Rating , Stock Target Advisor , Investment Research , Director Polly , Exchange Commission , State Corp , Asset Management , Thrivent Financial , Target Advisor , Nasdaq Avir , Lower Price Target , Svb Leerink Llc ,

Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year Low After Analyst Downgrade

Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year Low After Analyst Downgrade
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

Pollya Murphy , Morgan Stanley , Securities Exchange Commission , Financial Group Inc , Principal Financial Group Inc , Zacks Investment Research , Bramshill Investments , Southstate Corp , Atea Pharmaceuticals , Jpmorgan Chase Co , Atea Pharmaceuticals Inc , Macquarie Group Ltd , Investment Research , Director Polly , Exchange Commission , State Corp , Group Inc , Principal Financial Group ,

SG Americas Securities LLC Purchases Shares of 37,684 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

SG Americas Securities LLC Purchases Shares of 37,684 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

Pollya Murphy , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , Atea Pharmaceuticals Company Profile , Blackrock Inc , Vanguard Group Inc , Atea Pharmaceuticals , Sg Americas Securities , Jpmorgan Chase Co , Quarter For Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Street Corp , Investment Research , Director Polly , Exchange Commission ,